AlphAIAlphAI — Financial news for AI agents
SEC EDGAROCT 71 min read$PCVX

Cowan Elvia sold $1.6M of PCVX

Cowan Elvia (SVP, Finance & CAO) sold 19,000 shares of Vaxcyte, Inc. (PCVX) at $86.74 ($1.65M total) on 2026-10-05 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Cowan Elvia
Published Oct 7, 2026, 8:07 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 7, 2026, 8:11 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefInsider activity
Primary signal
$PCVX
Bearish
medium confidence
Mentioned
$PCVX
Relevance
5/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$PCVXBearishLow
01

Why it matters

The disclosed sale adds new information about insider activity, but its modest size limits market impact.

02

Market read

Primary insider sale filing; modest pressure expected on PCVX.

03

What to watch

Potential upcoming financing or dilution events not disclosed.

Relevance 5/10Novelty 5/10Timing: today

Background

SEC Form 4 filing provides the first public disclosure of the insider transaction.

Company-level read

Ticker impact

$PCVXBearishMedium confidence
Context

Form 4 disclosed a $1.65M open‑market sale of 19,000 shares by SVP of Finance, indicating insider divestment.

Expected impact

likely modest pressure as the market prices the insider sell.

Evidence & confidence

The sale size is modest relative to market cap, but insider selling often prompts short‑term downside bias.

Market effects

Sector

Minimal impact on the broader biotech sector.

Regional

No significant regional effect.

Global

Limited to Vaxcyte shareholders.

Counterpoint

What could challenge this read

The sale could be routine portfolio rebalancing, not a bearish signal.

Key entities

  • Insider
    Cowan Elvia

    SVP, Finance & CAO at Vaxcyte, reporting the sale.

  • Company
    Vaxcyte, Inc.

    Biotech firm developing vaccine technologies.

Read at source← All news

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

PCVX insider trading history →

Related articles

OCT 9
$PCVXHighAI 9/10

Vaxcyte Announces Closing of $1.15 Billion Public Offerings of Common Stock, Pre-Funded Warrants and Convertible Senior Notes, Including Full Exercise of Underwriters’ Options to Purchase Additional Shares and Convertible Senior Notes

Vaxcyte (PCVX) closed public offerings raising $1.15B, including 8.58M shares at $64 each, pre-funded warrants, and $575M in convertible notes. Proceeds will fund clinical trials, manufacturing, and R&D. Joint bookrunners included Jefferies, Leerink, and BofA.

marketscreener.com2 min
OCT 9
$MRNAHighAI 8/10

A New War on Cancer? NIH's Vaccine Initiative Sparks Biotech Stock Rally - Moderna (NASDAQ:MRNA), BioNTec

A new NIH initiative to accelerate personalized cancer vaccine development has sparked a rally in biotech stocks. Moderna, Novavax, BioNTech, Pfizer, Merck, and Vaxcyte saw gains. The program, launching in December, focuses on pancreatic, liver, colorectal cancers, and childhood tumors. Moderna and Merck reported positive Phase 3 results for their mRNA cancer vaccine in August. BioNTech is advancing multiple cancer therapies.

benzinga.com2 min